ARCHIMED Diagnostics – the Diagnostics team of global private equity healthcare specialist ARCHIMED – has closed its carve-out of Freemont, California-based ARK Diagnostics from listed South Korean specialty chemical company, Soulbrain Holdings. ARK is ARCHIMED Diagnostics’ third investment in 2025. The transaction gives ARK an enterprise value of $428 million. ARK is a global leader in the development and manufacture of specialty immunoassay In Vitro Diagnostics, with a focus on Therapeutic Drug Monitoring (ensuring the amount of drugs taken by patients is safe and effective), and Drugs of Abuse testing for human and veterinary applications.
Read the full article: ARCHIMED Diagnostics Closes Its Acquisition of ARK Diagnostics, a Global Leader in Disease and Drug Monitoring & Detection //
Source: https://archimed.group/news/archimed-diagnostics-closes-its-acquisition-of-ark-diagnostics-a-global-leader-in-disease-and-drug-monitoring-detection/